Eli Lilly and Company (LLY) Position Boosted by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. lifted its position in Eli Lilly and Company (NYSE:LLY) by 0.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 163,756 shares of the company’s stock after purchasing an additional 1,300 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in Eli Lilly and were worth $14,008,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Chicago Equity Partners LLC boosted its holdings in shares of Eli Lilly and by 20.1% in the 3rd quarter. Chicago Equity Partners LLC now owns 3,880 shares of the company’s stock worth $332,000 after purchasing an additional 650 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its holdings in shares of Eli Lilly and by 1.7% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 237,040 shares of the company’s stock worth $20,276,000 after purchasing an additional 3,872 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its holdings in shares of Eli Lilly and by 0.8% in the 3rd quarter. State Board of Administration of Florida Retirement System now owns 1,426,721 shares of the company’s stock worth $122,042,000 after purchasing an additional 11,922 shares in the last quarter. Dupont Capital Management Corp boosted its holdings in shares of Eli Lilly and by 125.1% in the 3rd quarter. Dupont Capital Management Corp now owns 103,148 shares of the company’s stock worth $8,823,000 after purchasing an additional 57,317 shares in the last quarter. Finally, Andra AP fonden boosted its holdings in Eli Lilly and by 3.2% during the 3rd quarter. Andra AP fonden now owns 225,400 shares of the company’s stock valued at $19,281,000 after acquiring an additional 6,900 shares during the period. Hedge funds and other institutional investors own 76.42% of the company’s stock.

In other news, major shareholder Lilly Endowment Inc sold 190,000 shares of the stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $82.53, for a total value of $15,680,700.00. Following the completion of the transaction, the insider now owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Alfonso G. Zulueta sold 2,003 shares of the stock in a transaction that occurred on Friday, November 10th. The stock was sold at an average price of $83.67, for a total value of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The disclosure for this sale can be found here. Insiders sold a total of 628,588 shares of company stock valued at $53,399,536 in the last three months. Corporate insiders own 0.20% of the company’s stock.

Several brokerages recently weighed in on LLY. BMO Capital Markets restated a “sell” rating and set a $71.00 target price on shares of Eli Lilly and in a report on Thursday, September 28th. Cowen restated a “buy” rating and set a $95.00 target price on shares of Eli Lilly and in a report on Wednesday, October 4th. Jefferies Group restated a “buy” rating and set a $89.00 target price (down from $94.00) on shares of Eli Lilly and in a report on Thursday, August 24th. BidaskClub cut Eli Lilly and from a “hold” rating to a “sell” rating in a report on Tuesday, August 22nd. Finally, Piper Jaffray Companies restated a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a report on Friday, October 13th. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $90.25.

Eli Lilly and Company (NYSE LLY) traded up $0.22 on Tuesday, reaching $86.67. The company’s stock had a trading volume of 3,336,800 shares, compared to its average volume of 3,672,243. The company has a market cap of $95,189.66, a price-to-earnings ratio of 21.14, a price-to-earnings-growth ratio of 1.90 and a beta of 0.35. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.38 and a quick ratio of 1.03. Eli Lilly and Company has a fifty-two week low of $67.42 and a fifty-two week high of $89.09.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, beating analysts’ consensus estimates of $1.03 by $0.02. Eli Lilly and had a return on equity of 30.27% and a net margin of 9.90%. The business had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same quarter in the prior year, the company posted $0.88 EPS. Eli Lilly and’s quarterly revenue was up 9.0% compared to the same quarter last year. analysts anticipate that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be given a $0.5625 dividend. This represents a $2.25 annualized dividend and a dividend yield of 2.60%. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. Eli Lilly and’s dividend payout ratio is currently 98.58%.

ILLEGAL ACTIVITY WARNING: “Eli Lilly and Company (LLY) Position Boosted by Mn Services Vermogensbeheer B.V.” was originally posted by Transcript Daily and is the property of of Transcript Daily. If you are reading this article on another publication, it was illegally copied and republished in violation of United States & international trademark and copyright law. The legal version of this article can be read at https://transcriptdaily.com/2017/12/12/eli-lilly-and-company-lly-position-boosted-by-mn-services-vermogensbeheer-b-v.html.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply